Arvinas (ARVN) Change in Account Payables (2017 - 2022)
Arvinas (ARVN) posted quarterly Change in Account Payables of -$22.6 million for Q1 2022, down 1355.56% year-over-year from $1.8 million in Q1 2021, and down 186.17% quarter-over-quarter from $26.2 million in Q4 2021.
Analysis
Arvinas (ARVN) Change in Account Payables (2017 - 2022) Analysis & Trends
Arvinas' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$22.6 million for Q1 2022.
- In Q1 2022, Change in Account Payables fell 1355.56% year-over-year to -$22.6 million; the TTM figure through Mar 2022 stood at -$700000.0 (down 112.26% YoY), while the FY2021 annual figure was $23.7 million, up 1085.0% from the prior year.
- Change in Account Payables for Q1 2022 stood at -$22.6 million, down from $26.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $26.2 million in Q4 2021, with the low at -$22.6 million in Q1 2022.
- The 5-year median for Change in Account Payables is $284784.0 (2019), against an average of $388362.5.
- The sharpest annual moves came in 2021 and 2022: Change in Account Payables surged 1067.29% in 2021, then slumped 1355.56% in 2022.
- Arvinas' Change in Account Payables stood at $1.3 million in 2018, then soared by 63.26% to $2.1 million in 2019, then grew by 6.03% to $2.2 million in 2020, then soared by 1067.29% to $26.2 million in 2021, then plunged by 186.17% to -$22.6 million in 2022.
- Business Quant data shows ARVN's Change in Account Payables at -$22.6 million in Q1 2022, $26.2 million in Q4 2021, and -$82863.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | -22.60 Mn |
| Dec 31, 2021 | 26.23 Mn |
| Sep 30, 2021 | -82,863.00 |
| Jun 30, 2021 | -4.24 Mn |
| Mar 31, 2021 | 1.80 Mn |
| Dec 31, 2020 | 2.25 Mn |
| Sep 30, 2020 | 2.03 Mn |
| Jun 30, 2020 | -367,912.00 |
| Mar 31, 2020 | -1.91 Mn |
| Dec 31, 2019 | 2.12 Mn |
| Sep 30, 2019 | 800,497.00 |
| Jun 30, 2019 | 284,784.00 |
| Mar 31, 2019 | -1.70 Mn |
| Dec 31, 2018 | 1.30 Mn |
| Sep 30, 2018 | -355,818.00 |
| Jun 30, 2018 | -310,156.00 |
| Mar 31, 2018 | 1.37 Mn |
| Dec 31, 2017 | -321,451.00 |